Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Chun‐Gon Kim(Korea Advanced Institute of Science and Technology), Kyoung‐Ho Kim(Korea Advanced Institute of Science and Technology), Kyoung‐Ho Pyo(Cancer Research UK), C.-F. Xin, Min Hee Hong, Beung‐Chul Ahn, Y. Kim(Korea Advanced Institute of Science and Technology), Seong Jin Choi(Korea Advanced Institute of Science and Technology), Hong In Yoon(Yonsei University), J.G. Lee, C.Y. Lee, Sung Yong Park(Korea Advanced Institute of Science and Technology), S.-H. Park(Korea Advanced Institute of Science and Technology), Byoung Chul Cho, Hyo Sup Shim(Yonsei University), Eui‐Cheol Shin(Korea Advanced Institute of Science and Technology), H.R. Kim(Nobel Foundation)
Cited by 301Open Access
Abstract
Related Papers
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al.|New England Journal of Medicine|2016|10k
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al.|New England Journal of Medicine|2018|6.6k